The Cut: Can my acne products cause cancer?
The University of Cincinnati's Kelly Dobos spoke with The Cut about the risk of benzene exposure in common acne products.
Recently, an independent laboratory filed a petition with the Food and Drug Administration requesting the recall of products that contain an over-the-counter acne-treating drug called benzoyl peroxide due to elevated levels of the carcinogen benzene.
“Unless someone is keeping their acne treatment in a car during the hottest days of summer, it’s incredibly unlikely your product will experience that kind of condition" of increased benzene exposure, Dobos, a cosmetic chemist and adjunct instructor in UC's Cosmetic Science Program in the James L. Winkle College of Pharmacy, told The Cut.
Dobos noted most people are exposed to at least some level of benzene every day, regardless of the acne products they use. People can experience elevated levels when cooking over a gas flame, putting fuel in your car or sitting next to a person who is vaping or smoking.
“According to information from the World Health Organization, outdoor air has a background benzene level ranging from 0.31 parts per billion in rural areas to 1.5 to 2.3 parts per billion in suburbs and cities," she said.
Featured photo at top of a woman washing her face. Photo/Extreme Photographer/iStock.
Related Stories
UC biologist talks about 'pearmageddon'
March 16, 2026
WLWT talks to UC biologist and Department Head Theresa Culley about invasive, nonnative Callery pear trees that are spreading across Ohio forests after they were introduced by landscapers more than 50 years ago.
Local media highlight completion of Blood Cancer Healing Center fourth and fifth floors
March 16, 2026
Local media including WLWT and the Cincinnati Business Courier highlighted the opening of research laboratories and the UC Osher Wellness Suite and Learning Kitchen at the University of Cincinnati Cancer Center’s Blood Cancer Healing Center.
Trial results support weekly buprenorphine treatment of opioid use disorder during pregnancy
March 16, 2026
Supported by the National Institutes of Health (NIH), researchers led by the University of Cincinnati's John Winhusen published clinical trial results in JAMA Internal Medicine that found administering weekly injectable extended-release buprenorphine for treatment of opioid use disorder during pregnancy led to higher rates of abstinence from illicit opioids than buprenorphine given daily under the tongue, one of the standard methods of treatment.